AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36000374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A eye gel combined with 3M transparent tape
Number of subjects: 120
Study 36000374 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin eye ointment combined with 3M transparent tape
Number of subjects: 120
Study 32232645 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DMax™ mesh
Number of subjects: 48
Study 32232645 — intervention group
Group type: COMPARATOR
Intervention: Ultrapro® mesh
Number of subjects: 48
Study 32232645 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic mesh placement
Number of subjects: 48
Study 32232645 — intervention group
Group type: EXPERIMENTAL
Intervention: NASA-TLX self-assessment surveys
Number of subjects: 48
Study 33310488 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-induction
Number of subjects: 29
Study 33310488 — intervention group
Group type: COMPARATOR
Intervention: Neutral-induction
Number of subjects: 29
Study 32913021 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram × 2 weeks
Number of subjects: 114
Study 32913021 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram × 8 weeks
Number of subjects: 114
Study 32913021 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg escitalopram × 8 weeks
Number of subjects: 114
Study 32913021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 35777494 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and progesterone addback for 8 weeks
Number of subjects: 30
Study 35777494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone withdrawal
Number of subjects: 30
Study 32091593 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based menu-planning tool and support
Number of subjects: 522
Study 32091593 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 522
Study 36301305 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Adolescent (PA) treatment condition
Number of subjects: 0
Study 36301305 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 36301305 — intervention group
Group type: COMPARATOR
Intervention: Parent-only condition
Number of subjects: 0
Study 34663649 — intervention group
Group type: EXPERIMENTAL
Intervention: MALDI‐TOF mass spectrometry
Number of subjects: 5550
Study 34663649 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of microbial identification
Number of subjects: 5550
Study 32089456 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C goal <50 mg/dL for all patients in secondary prevention or very high-risk primary prevention; optional goal ≤30 mg/dL for category A extreme-risk patients; recommended goal ≤30 mg/dL for category B extreme-risk patients.
Number of subjects: 162
Study 32089456 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of statins and ezetimibe
Number of subjects: 162
Study 32089456 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprotein convertase subtilisin kexin type 9 inhibitors
Number of subjects: 162
Study 36397083 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and care prior to surgery, in addition to standard protocol.
Number of subjects: 0
Study 36397083 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA and care prior to surgery, in addition to standard protocol.
Number of subjects: 0
Study 36397083 — intervention group
Group type: COMPARATOR
Intervention: Best known practice as stipulated by Swedish colorectal cancer treatment guidelines within an enhanced recovery after surgery (ERAS) setting.
Number of subjects: 0
Study 32109221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCA with remifentanil
Number of subjects: 155
Study 32109221 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with programmed intermittent bolus dosing
Number of subjects: 155
Study 32109221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 155
Study 35603874 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct handwashing training
Number of subjects: 105
Study 35603874 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct mask-wearing training
Number of subjects: 105
Study 35603874 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 105
Study 32799959 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic food consumption
Number of subjects: 3896
Study 32799959 — intervention group
Group type: COMPARATOR
Intervention: Control for confounding variables (socio-economic status, quality of diet, physical activity)
Number of subjects: 3896
Study 35610265 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening blue-depleted light environments (BDLE)
Number of subjects: 12
Study 34133856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg twice daily for up to 14 days)
Number of subjects: 289
Study 34133856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for up to 14 days)
Number of subjects: 289
Study 32631366 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of purchase prompts (PPPs) displayed in intervention shops (n = 15)
Number of subjects: 30
Study 32631366 — intervention group
Group type: COMPARATOR
Intervention: No point of purchase prompts in control shops (n = 15)
Number of subjects: 30
Study 36008352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid volume quartile 1 (89-882 ml)
Number of subjects: 4671
Study 36008352 — intervention group
Group type: COMPARATOR
Intervention: Fluid volume quartile 4 (1258-2790 ml)
Number of subjects: 4671
Study 36008352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration of 1000 ml starting at least 1 hour before contrast injection and continuing for 6 hours
Number of subjects: 4671
Study 36008352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean fluid volumes <964 ml
Number of subjects: 4671
Study 34535488 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus activity monitor and customised education, motivation and support delivered via text messaging
Number of subjects: 180
Study 34535488 — intervention group
Group type: COMPARATOR
Intervention: Usual care with activity monitor (active control)
Number of subjects: 180
Study 36151537 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria prevention education (MPE)
Number of subjects: 0
Study 34320864 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 30
Study 34320864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil 1% cream
Number of subjects: 30
Study 33892831 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered one percent lidocaine (3 mL including 0.3 mL of 8.4 percent sodium bicarbonate)
Number of subjects: 25
Study 33892831 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered two percent lidocaine (3 mL)
Number of subjects: 25
Study 34157578 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methotrexate (MTX) per week
Number of subjects: 64
Study 34157578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 32470924 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract (CurraNZ™) 300 mg/day
Number of subjects: 20
Study 32470924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 616545791 — intervention group
Group type: EXPERIMENTAL
Intervention: TEXT ME intervention (text message-based intervention providing advice, motivation, information, and support)
Number of subjects: 50000
Study 36329165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein Angiography (FA) guided laser treatment
Number of subjects: 30
Study 36329165 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser treatment
Number of subjects: 30
Study 33527192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary anesthesia (ILA)
Number of subjects: 72
Study 33527192 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (IANB)
Number of subjects: 72
Study 33514869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (100 ml of Lactobacillus casei strain Shirota)
Number of subjects: 158
Study 33514869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (200 ml of Lactobacillus casei strain Shirota)
Number of subjects: 158
Study 33514869 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (100 ml of special drinks without active Lactobacillus casei)
Number of subjects: 158
Study 33514869 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (20 healthy people)
Number of subjects: 158
Study 34024606 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum feeding at 12 h after birth (TRT12h)
Number of subjects: 22
Study 34024606 — intervention group
Group type: COMPARATOR
Intervention: Colostrum feeding at 45 min and 6 h after birth
Number of subjects: 22
Study 32324471 — intervention group
Group type: EXPERIMENTAL
Intervention: Block-structured training alternating weekly between blood flow restricted low-load resistance training (BFR-RT) at 20% 1-RM and heavy-load resistance training (HL-RT) at 70-90% 1-RM (BFR-HRT, n = 9)
Number of subjects: 18
Study 32324471 — intervention group
Group type: COMPARATOR
Intervention: Heavy-load resistance training (HL-RT, n = 9)
Number of subjects: 18
Study 91343853 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0
Study 91343853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35922444 — intervention group
Group type: EXPERIMENTAL
Intervention: midostaurin
Number of subjects: 475
Study 35922444 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 475
Study 35067831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauti ya Vijana (SYV) intervention
Number of subjects: 105
Study 35067831 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 105
Study 33534382 — intervention group
Group type: EXPERIMENTAL
Intervention: High limbal clearance scleral lenses
Number of subjects: 22
Study 33534382 — intervention group
Group type: COMPARATOR
Intervention: Low limbal clearance scleral lenses
Number of subjects: 22
Study 32028486 — intervention group
Group type: EXPERIMENTAL
Intervention: POP repair with mesh
Number of subjects: 54194
Study 32028486 — intervention group
Group type: COMPARATOR
Intervention: POP repair without transvaginal mesh (nonmesh)
Number of subjects: 54194
Study 32028486 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinterventions related to mesh complications
Number of subjects: 54194
Study 35926074 — intervention group
Group type: EXPERIMENTAL
Intervention: Curated social web app for COVID-19 vaccine information
Number of subjects: 592
Study 35926074 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with LTCWs (n=9)
Number of subjects: 592
Study 35926074 — intervention group
Group type: EXPERIMENTAL
Intervention: LTCW poll (n=8)
Number of subjects: 592
Study 35926074 — intervention group
Group type: EXPERIMENTAL
Intervention: Community building efforts with LTCW ambassadors
Number of subjects: 592
Study 33077275 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre flatbread with enzymatically released free FA (14.22 mg)
Number of subjects: 19
Study 33077275 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard high fibre bread (2.34 mg)
Number of subjects: 19
Study 33077275 — intervention group
Group type: COMPARATOR
Intervention: White bread control (0.48 mg)
Number of subjects: 19
Study 33169661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue vaccine
Number of subjects: 10157
Study 33169661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10157
Study 33197654 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2 mA for 20 min
Number of subjects: 62
Study 33197654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 32522124 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich gruel (atole)
Number of subjects: 0
Study 32522124 — intervention group
Group type: COMPARATOR
Intervention: Nonprotein, low-energy drink (fresco)
Number of subjects: 0
Study 34489100 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen infiltrations (3-5 sessions)
Number of subjects: 15
Study 34489100 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment (Control Group)
Number of subjects: 15
Study 33932397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH)
Number of subjects: 14
Study 33932397 — intervention group
Group type: COMPARATOR
Intervention: Sham AIH
Number of subjects: 14
Study 32119926 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-integrated collaborative care intervention
Number of subjects: 424
Study 32119926 — intervention group
Group type: COMPARATOR
Intervention: Surgical team notification (enhanced usual care)
Number of subjects: 424
Study 36204877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol injection combined with 125I radioactive seed implantation
Number of subjects: 10
Study 36204877 — intervention group
Group type: COMPARATOR
Intervention: Ethanol injection alone
Number of subjects: 10
Study 34259407 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin's three‐needle combined with Tongdu Tiaoshen acupuncture
Number of subjects: 60
Study 34259407 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training and routine acupuncture
Number of subjects: 60
Study 32183895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger supplementation (dosage not specified)
Number of subjects: 44
Study 32183895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dosage not specified)
Number of subjects: 44
Study 34655326 — intervention group
Group type: EXPERIMENTAL
Intervention: ECAU plus self‐guided CBT and SmartCare©
Number of subjects: 120
Study 34655326 — intervention group
Group type: EXPERIMENTAL
Intervention: ECAU plus SmartCare©
Number of subjects: 120
Study 34655326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group (SmartCare© with or without CBT)
Number of subjects: 120
Study 34655326 — intervention group
Group type: COMPARATOR
Intervention: ECAU only
Number of subjects: 120
Study 32485778 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation plus caloric restriction
Number of subjects: 25
Study 32485778 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction alone
Number of subjects: 25
Study 34936057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 253
Study 34936057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 34781969 — intervention group
Group type: EXPERIMENTAL
Intervention: On-the-spot pregnancy test (N=170)
Number of subjects: 810
Study 34781969 — intervention group
Group type: EXPERIMENTAL
Intervention: Future-use pregnancy test (N=163)
Number of subjects: 810
Study 34781969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both on-the-spot and future-use pregnancy tests (N=153)
Number of subjects: 810
Study 34781969 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=324)
Number of subjects: 810
Study 32526606 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwifery continuity of care
Number of subjects: 18
Study 32526606 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 616569131 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail 'antirotation' (PFNa)
Number of subjects: 140
Study 616569131 — intervention group
Group type: COMPARATOR
Intervention: Sliding Hip Screw (SHS)
Number of subjects: 140
Study 35357105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei (1 × 10^10 CFU/day)
Number of subjects: 47
Study 35357105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei (2 × 10^10 CFU/day)
Number of subjects: 47
Study 35357105 — intervention group
Group type: COMPARATOR
Intervention: Standard antituberculosis therapy only (Control group)
Number of subjects: 47
Study 34330608 — intervention group
Group type: EXPERIMENTAL
Intervention: Condylar apex method
Number of subjects: 93
Study 34330608 — intervention group
Group type: COMPARATOR
Intervention: Condylar centre method
Number of subjects: 93
Study 34330608 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction of the TMJ structure
Number of subjects: 93
Study 34330608 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of disc position between genders
Number of subjects: 93
Study 34330608 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of left and right TMJ disc–condyle position
Number of subjects: 93
Study 33580673 — intervention group
Group type: COMPARATOR
Intervention: Variants at six loci associated with SSS including a missense variant in MYH6 and variants at PITX2, ZFHX3, TTN/CCDC141, SCN10A, and KRT8.
Number of subjects: 6469
Study 33580673 — intervention group
Group type: COMPARATOR
Intervention: Mendelian randomization analysis for AF and lower heart rate.
Number of subjects: 6469
Study 33580673 — intervention group
Group type: COMPARATOR
Intervention: Powerful PGS analyses.
Number of subjects: 6469
Study 32505382 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo diagnostics
Number of subjects: 0
Study 32505382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous validation of embryo diagnostics
Number of subjects: 0
Study 36123843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection preoperatively
Number of subjects: 0
Study 36123843 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey locally in the wound after extraction
Number of subjects: 0
Study 36123843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection preoperatively and topical honey application
Number of subjects: 0
Study 36123843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 36123843 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 36123843 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (Dexamethasone and honey)
Number of subjects: 0
Study 34032731 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin (150 mg/d for 3 months)
Number of subjects: 51
Study 34032731 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Diane-35, 1 tablet/d, orally, plus metformin, 1.5 g/d, orally)
Number of subjects: 51
Study 34032731 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus puerarin
Number of subjects: 51
Study 32783667 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors (CDK4/6i)
Number of subjects: 88
Study 35752175 — intervention group
Group type: EXPERIMENTAL
Intervention: Video educational intervention prior to simulation-1 (n=83)
Number of subjects: 166
Study 35752175 — intervention group
Group type: EXPERIMENTAL
Intervention: Video educational intervention between simulation-1 and simulation-2 (n=83)
Number of subjects: 166
Study 32797375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis BS01 and Lactobacillus acidophilus LA02 supplementation
Number of subjects: 53
Study 32797375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 35089372 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (Group I)
Number of subjects: 320
Study 35089372 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 0.25 mg/kg (Group II)
Number of subjects: 320
Study 35089372 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 0.5 mg/kg (Group III)
Number of subjects: 320
Study 35089372 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1.0 mg/kg (Group IV)
Number of subjects: 320
Study 33049411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (1 g at 4, 10, and 16 hours postoperatively)
Number of subjects: 108
Study 33049411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (0.5 g at 6, 12, and 18 hours postoperatively)
Number of subjects: 108
Study 33049411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 35987548 — intervention group
Group type: EXPERIMENTAL
Intervention: Accept Yourself! (AY)
Number of subjects: 19
Study 35987548 — intervention group
Group type: COMPARATOR
Intervention: Weight Watchers (WW)
Number of subjects: 19
Study 35987548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AY and WW)
Number of subjects: 19
Study 32057988 — intervention group
Group type: EXPERIMENTAL
Intervention: ARPF
Number of subjects: 77
Study 32057988 — intervention group
Group type: COMPARATOR
Intervention: ORIF
Number of subjects: 77
Study 35020796 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin D3
Number of subjects: 200
Study 35020796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 34304322 — intervention group
Group type: EXPERIMENTAL
Intervention: PGPR strain Mn‐6
Number of subjects: 0
Study 34304322 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS‐producing PGPR (various strains)
Number of subjects: 0
Study 34304322 — intervention group
Group type: COMPARATOR
Intervention: Control (non‐inoculated treatment)
Number of subjects: 0
Study 32658327 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with higher seizure frequencies and lower standard deviations during their baseline
Number of subjects: 0
Study 32658327 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical trial design with patients included
Number of subjects: 0
Study 32658327 — intervention group
Group type: COMPARATOR
Intervention: Typical trial design without patients included
Number of subjects: 0
Study 33814186 — intervention group
Group type: EXPERIMENTAL
Intervention: Two stage Fowler-Stephens laparoscopic orchiopexy (FSLO)
Number of subjects: 45
Study 33814186 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged laparoscopic traction orchiopexy (SLTO)
Number of subjects: 45
Study 32064975 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% tretinoin microspheres plus 1% clindamycin
Number of subjects: 0
Study 32064975 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33998778 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based Liuzijue exercise (WG)
Number of subjects: 50
Study 33998778 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based Liuzijue exercise (LG)
Number of subjects: 50
Study 33998778 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 32057275 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Whole Slide Imaging (WSI)
Number of subjects: 2045
Study 32057275 — intervention group
Group type: COMPARATOR
Intervention: Light Microscopy (glass slides)
Number of subjects: 2045